INFLUENCE OF CONFORMAL RADIOTHERAPY IN COMBINATION WITH RADIOMODIFIERS ON THE CONTENT OF VEGF, COX-2, AND PGE-2 IN BLOOD SERUM OF PATIENTS WITH HEAD AND NECK SQUAMOUS CELL CARCINOMA

Authors

  • N. MITRYAYEVA State Organization «Grigoriev Institute for Medical Radiology and Oncology of the National Academy of Medical Sciences of Ukraine», Kharkiv, Ukraine
  • L. GREBINYK State Organization «Grigoriev Institute for Medical Radiology and Oncology of the National Academy of Medical Sciences of Ukraine», Kharkiv, Ukraine
  • S. ARTIUKH State Organization «Grigoriev Institute for Medical Radiology and Oncology of the National Academy of Medical Sciences of Ukraine», Kharkiv, Ukraine
  • N. BILOZOR State Organization «Grigoriev Institute for Medical Radiology and Oncology of the National Academy of Medical Sciences of Ukraine», Kharkiv, Ukraine
  • V. STARENKIY State Organization «Grigoriev Institute for Medical Radiology and Oncology of the National Academy of Medical Sciences of Ukraine», Kharkiv, Ukraine

DOI:

https://doi.org/10.15407/exp-oncology.2024.03.253

Keywords:

head and neck squamous cell carcinoma, radiation therapy, COX-2 inhibitor, cisplatin, vascular endothelial growth factor, cyclooxygenase-2, prostaglandin E-2

Abstract

Background. The development of new approaches to modeling tumor radiosensitivity in patients with head and neck squamous cell carcinoma (HNSCC) is an important problem for overcoming tumor radioresistance. New agents for radiomodification are inhibitors of the enzyme cyclooxygenase-2 (COX-2). The study of markers of radioresistance in cancer patients undergoing radiotherapy (RT) in combination with COX-2 inhibitors and chemotherapy may contribute to the effectiveness of RT. Aim. To determine the effect of conformal RT in combination with radiomodifiers (celecoxib, cisplatin, or their combination) on the content of vascular endothelial growth factor (VEGF), COX-2, and prostaglandin E-2 (PGE-2) in the serum of patients with HNSCC. Materials and Methods. 47 patients with HNSCC were divided into 4 groups: RT in combination with celecoxib and cisplatin, RT with cisplatin, RT with celecoxib, and RT. Patients received radiation treatment on a Clinac 600C linear accelerator. The levels of VEGF, COX-2, and PGE-2 in the serum were determined by enzyme immunoassay. Results. Blocking COX-2 in patients with HNSCC leads to a decrease in VEGF levels. The largest decrease in VEGF levels was observed in a group treated by RT in combination with celecoxib and cisplatin, indicating a more effective antiangiogenic effect. The changes in the levels of VEGF, COX-2, and PGE-2, which are most pronounced under the combined effect of RT and both radiomodifiers, coincided with an objective response to radiation treatment. Conclusions. The data obtained indicate the effect of radiomodification on the suppression of angiogenesis, which is most pronounced under the combined effect of RT and both radiomodifiers. The decrease in the levels of PGE- 2, COX-2, and VEGF coincides with the clinical efficacy of radiotherapy according to RECIST 1.1 criteria.

References

Fedorenko ZP, Gulak LO, Gorokh EL, et al. Cancer in Ukraine, 2020­2021. Incidence, mortality, performance indi­ cators of the oncology service. Bull Nat Cancer Reg Ukraine, 2022. Accessed from: http://www.ncru.inf.ua/publica­ tions/BULL_24/index_e.htm

Kim DY, Wu HG, Kim JH, et al. Radiotherapy versus surgery in early­stage HPV­positive oropharyngeal cancer.

Cancer Res Treat. 2022;54(2):406­416. https://doi.org/10.4143/crt.2021.441

Gately S, Kerbel R. Therapeutic potential of selective cyclooxygenase­2 inhibitors in the management of tumor an­ giogenesis. Prog Exp Tumor Res. 2003;37:179­192. https://doi.org/10.1159/000071373. PMID: 12795055.

Mitryaeva N, Starenkyi V, Bilozor N, et al. Radiosensitization with Cyclooxygenase-2 Inhibitors in Radiation Therapy of Malignant Tumors. Kharkiv: IMRO, 2021. 136 p. ISBN 978­966­96633­8­2 (in Ukrainian).

Mitryaeva NA, Grebinik LV, Uzlenkova NE. Effect of combined action of X­radiation and COX­2 inhibitor meloxivet on the content of VEGF and PGE­2 in the blood serum of tumor­bearing rats. Probl Rad Med Radiobiol. 2019;24;261­ 269. https://doi.org/10.33145/2304­8336­2019­24­231­269

Chiang KH, Shieh JM, Shen CJ, et al. Epidermal growth factor­induced COX­2 regulates metastasis of head and neck squamous cell carcinoma through upregulation of angiopoietin­like. Cancer Sci. 2020;111(6):2004­2015. https://doi. org/10.1111/cas.14400

Yokouchi H, Kanazawa K. Revisiting the role of COX­2 inhibitor for non­small cell lung cancer. Transl Lung Cancer Res. 2015;4(5): 660­664. https://doi.org/10.3978/j.issn.2218­6751.2015.04.03

Santoro A, Bufo P, Russo G, et al. Expression and clinical implication of cyclooxygenase­2 and E­cadherin in oral squamous cell carcinomas Cancer Biol Ther. 20202;(8):667­674. https://doi.org/10.1080/15384047.2015.1071741

Xu L, Stevens J, Hilton M, et al. COX­2 inhibition potentiates antiangiogenic cancer therapy and prevents metastasis in preclinical models. Sci Transl Med. 201425;6(242):242ra84. https://doi.org/10.1126/scitranslmed.3008455

Cheki M, Yahyapour R, Farhood B, et al. COX­2 in radiotherapy: a potential target for radioprotection and radiosen­ sitization. Curr Mol Pharmacol. 2018;11(3):173­183. https://doi.org/10.2174/1874467211666180219102520

Han Z, Liao H, Shi F, et al. Inhibition of cyclooxygenase­2 sensitizes lung cancer cells to radiation­induced apoptosis.

Oncol Lett. 2017;14(5):5959­5965. https://doi.org/10.3892/ol.2017.6940

Laube M, Kniess T, Pietzsch J. Development of antioxidant COX­2 inhibitors as radioprotective agents for radiation therapy—a hypothesis­driven review. Antioxidants. 2016;5(2):14. https://doi.org/10.3390/antiox5020014

Peltanova B, Liskova M, Gumulec J, et al. Sensitivity to cisplatin in head and neck cancer cells is signifi antly affected by patient­derived cancer­associated fibroblasts. Int J Mol Sci. 2021;22(4):1912. https://doi.org/10.3390/ijms22041912

Head and Neck Cancers / NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) // Version 4.2024 — May 1, 2024. www.nccn.org/patients

Ang K, Zhang Q, Rosenthal D, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma. J Clin Oncol. 2014;32(27):2940­2950. https:// doi.org/10.1200/JCO.2013.53.5633

Li S, Jiang M, Wang L, Yu S. Combined chemotherapy with cyclooxygenase­2 (COX­2) inhibitors in treating human cancers: Recent advancement. Biomed Pharmacother. 2020;129:110389. https://doi.org/10.1016/j.biopha.2020.110389

Lundin E, Reizenstein J, Landstrom F, et al. Radiotherapy a selective treatment of the node­negative neck in oral squamous cell cancer. Anticancer Res. 2021;41(7):3489­3498. https://doi.org/10.21873/anticanres.15136.

Bilozor N, Artyukh S, Mitryaeva N, et al. The content of VEGF, COX­2, PGE­2 in the blood serum of patients with PCa in the dynamics of conformal radiation therapy. Ukr Radiol J. 2018;26(2):93­98 (in Ukrainian).

Ghosh S. Cisplatin: The first metal based anticancer drug. Bioorg Chem. 2019;88:102925. https://doi.org/10.1016/j. bioorg.2019.102925

Zhang CC, Li CG, Wang YF, et al. Chemotherapeutic paclitaxel and cisplatin differentially induce pyroptosis in A549 lung cancer cells via caspase­3/GSDME activation. Apoptosis. 2019;24(3­4):312­325. https://doi.org/10.1007/s10495­ 019­01515­1

Sofia Vala I, Martins LR, Imaizumi N, et al. Low doses of ionizing radiation promote tumor growth and metastasis by enhancing angiogenesis. PLoS One. 2010;5(6):e11222. https://doi.org/10.1371/journal.pone.0011222

Downloads

Published

19.12.2024

How to Cite

MITRYAYEVA, N., GREBINYK, L., ARTIUKH, S., BILOZOR, N., & STARENKIY, V. (2024). INFLUENCE OF CONFORMAL RADIOTHERAPY IN COMBINATION WITH RADIOMODIFIERS ON THE CONTENT OF VEGF, COX-2, AND PGE-2 IN BLOOD SERUM OF PATIENTS WITH HEAD AND NECK SQUAMOUS CELL CARCINOMA. Experimental Oncology, 46(3), 253–259. https://doi.org/10.15407/exp-oncology.2024.03.253

Issue

Section

Original contributions